|16.57||+0.3700||+2.28%||Vol 2.29M||1Y Perf -23.76%|
|Aug 11th, 2022 16:00 DELAYED|
|- -||0.33 1.99%|
|Target Price||25.36||Analyst Rating||Strong Buy 1.50|
|Potential %||53.05||Finscreener Ranking||★★★+ — -|
|Insiders Trans % 3/6/12 mo.||-100/-100/-79||Value Ranking||★★★+ 54.42|
|Insiders Value % 3/6/12 mo.||-100/-100/7||Growth Ranking||★★★ — -|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/9||Income Ranking||— -|
|Price Range Ratio 52W %||47.33||Earnings Rating||Strong Buy|
|Market Cap||2.38B||Earnings Date||9th Aug 2022|
Today's Price Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.61|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||2.06M|
|Avg. Monthly Volume||1.61M|
|Avg. Quarterly Volume||2.00M|
Allogene Therapeutics Inc. (NASDAQ: ALLO) stock closed at 16.57 per share at the end of the most recent trading day (a 2.28% change compared to the prior day closing price) with a volume of 2.29M shares and market capitalization of 2.38B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 265 people. Allogene Therapeutics Inc. CEO is David D. Chang.
The one-year performance of Allogene Therapeutics Inc. stock is -23.76%, while year-to-date (YTD) performance is 11.06%. ALLO stock has a five-year performance of %. Its 52-week range is between 6.425 and 27.86, which gives ALLO stock a 52-week price range ratio of 47.33%
Allogene Therapeutics Inc. currently has a PE ratio of -5.80, a price-to-book (PB) ratio of 2.15, a price-to-sale (PS) ratio of 11 149.10, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -28.35%, a ROC of -29.87% and a ROE of -31.57%. The company’s profit margin is -%, its EBITDA margin is -141 637.00%, and its revenue ttm is $161.00 Thousand , which makes it $0.00 revenue per share.
Of the last four earnings reports from Allogene Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.61 for the next earnings report. Allogene Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Allogene Therapeutics Inc. is Strong Buy (1.5), with a target price of $25.36, which is +53.05% compared to the current price. The earnings rating for Allogene Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Allogene Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Allogene Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.72, ATR14 : 1.20, CCI20 : 179.73, Chaikin Money Flow : 0.19, MACD : 1.12, Money Flow Index : 66.45, ROC : 22.29, RSI : 54.61, STOCH (14,3) : 88.49, STOCH RSI : 1.00, UO : 67.59, Williams %R : -11.51), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Allogene Therapeutics Inc. in the last 12-months were: Alison Moore (Sold 8 698 shares of value $66 388 ), Arie S. Belldegrun (Buy at a value of $1 953 491), David D. Chang (Sold 23 648 shares of value $180 879 ), Eric Schmidt (Sold 11 469 shares of value $87 551 ), Joshua A. Kazam (Buy at a value of $189 000), Owen N. Witte (Sold 20 000 shares of value $361 500 ), Rafael Amado (Sold 28 176 shares of value $405 125 ), Rafael G. Amado (Sold 32 176 shares of value $450 365 ), Veer Bhavnagri (Option Excercise at a value of $22 700), Veer Bhavnagri (Sold 18 849 shares of value $296 801 )
Sat, 05 Mar 2022 09:08 GMT Allogene Therapeutics (ALLO) Gets a Hold Rating from J.P. Morgan- TipRanks. All rights reserved.
Sun, 27 Feb 2022 10:51 GMT Allogene Therapeutics (ALLO) Gets a Buy Rating from RBC Capital- TipRanks. All rights reserved.
Tue, 11 Jan 2022 11:25 GMT Allogene Therapeutics (ALLO) Received its Third Buy in a Row- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.